ATI-1150
ATI-1150 is a PSN™ formulation of SN-38, which is the active metabolite of Pfizer’s drug CAMPTOSAR® that is used for the treatment of colorectal cancer. SN-38 is a topoisomerase inhibitor that induces protein-associated DNA single strand breakage during the DNA synthesis phase (S-phase) of the cell cycle, impeding cell division and causing cell death. SN-38 itself is 1,000 to 2,000 times more potent than CPT-11; however, it cannot be delivered directly to the patient in its current form due to its water insolubility and high systemic toxicity. ATI-1150 overcomes these obstacles by targeting the PSN-encapsulated SN-38 directly to the tumor site, and shielding the healthy cells from contact with the drug. ATI-1150 is currently in pre-clinical studies, and has been shown to be two to three times more efficient than CPT-11 in a nude mouse model of human colon cancer. Additional studies have been initiated and will be reported in the future.
